| 1. |
Nienhuis A. W., Walsh C. E., and Liu J. Viruses as therapeutic gene transfer vectors. In: Young N. S., ed. (1993) Viruses and Bone Marrow: Basic Research and Clinical Practice. New York: Dekker, 353–414.
|
| |
| 2. |
Markowitz, D., Goff, S., and Bank, A. (1988) Construction and use of a safe and efficient amphotropic packaging cell line.
Virology
167, 400–406.
|
| |
| 3. |
Markowitz, D. G., Goff, S. P., and Bank, A. (1988) Safe and efficient ecotropic and amphotropic packaging lines for use in
gene transfer experiments. Trans. Assoc. Am. Physicians
101, 212–218.
|
| |
| 4. |
Miller, A. D. (1990) Retrovirus packaging cells. Hum. Gene Ther. 1, 5–14.
|
| |
| 5. |
Kohno, T., Mohan, S., Goto, T., Morita, C., Nakano, T., Hong, W., Sangco, J. C., Morimatsu, S., and Sano, K. (2002) A new
improved method for the concentration of HIV-1 infective particles. J. Virol. Methods
106, 167–173.
|
| |
| 6. |
Baum, C., Dullmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., and von Kalle, C. (2003) Side effects of retroviral
gene transfer into hematopoietic stem cells. Blood
101, 2099–2114.
|
| |
| 7. |
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., and Serguera, C. (2006) Lentiviral
vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 17684–17689.
|
| |
| 8. |
Martin, P., Albagli, O., Poggi, M. C., Boulukos, K. E., and Pognonec, P. (2006) Development of a new bicistronic retroviral
vector with strong IRES activity. BMC. Biotechnol. 6, 4.
|
| |
| 9. |
Klump, H., Schiedlmeier, B., Vogt, B., Ryan, M., Ostertag, W., and Baum, C. (2001) Retroviral vector-mediated expression of
HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther. 8, 811–817.
|
| |
| 10. |
Amendola, M., Venneri, M. A., Biffi, A., Vigna, E., and Naldini, L. (2005) Coordinate dual-gene transgenesis by lentiviral
vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108–116.
|
| |
| 11. |
Zaboikin, M., Srinivasakumar, N., and Schuening, F. (2006) Gene therapy with drug resistance genes. Cancer Gene Ther. 13, 335–345.
|
| |
| 12. |
Milsom, M. D., Fairbairn, L. J. (2004) Protection and selection for gene therapy in the hematopoietic system. J. Gene Med. 6, 133–146.
|
| |
| 13. |
Flasshove, M., Moritz, T., Bardenheuer, W., and Seeber, S. (2003) Hematoprotection by transfer of drug-resistance genes. Acta Haematol. 110, 93–106.
|
| |
| 14. |
Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., and Nienhuis, A. W. (1997) Retroviral-mediated
transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced
progenitors in vitro and identification of genetically modified cells in vivo. Blood
90, 1777–1786.
|
| |
| 15. |
Hawley, T. S., Telford, W. G., and Hawley, R. G. (2001) “Rainbow” reporters for multispectral marking and lineage analysis
of hematopoietic stem cells. Stem Cells
19, 118–124.
|
| |
| 16. |
Persons, D. A., Allay, J. A., Riberdy, J. M., Wersto, R. P., Donahue, R. E., Sorrentino, B. P., and Nienhuis, A. W. (1998)
Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat. Med. 4, 1201–1205.
|
| |
| 17. |
Dick, J. E., Magli, M. C., Huszar, D., Phillips, R. A., and Bernstein, A. (1985) Introduction of a selectable gene into primitive
stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell
42, 71–79.
|
| |
| 18. |
Szilvassy, S. J., Fraser, C. C., Eaves, C. J., Lansdorp, P. M., Eaves, A. C., and Humphries, R. K. (1989) Retrovirus-mediated
gene transfer to purified hemopoietic stem cells with long-term lympho-myelopoietic repopulating ability. Proc. Natl. Acad. Sci. U.S.A. 86, 8798–8802.
|
| |
| 19. |
Fraser, C. C., Szilvassy, S. J., Eaves, C. J., and Humphries, R. K. (1992) Proliferation of totipotent hematopoietic stem
cells in vitro with retention of long-term competitive in vivo reconstituting ability. Proc. Natl. Acad. Sci. U.S.A. 89, 1968–1972.
|
| |
| 20. |
Hawley, R. G., Lieu, F. H., Fong, A. Z., and Hawley, T. S. (1994) Versatile retroviral vectors for potential use in gene therapy.
Gene Ther. 1, 136–138.
|
| |
| 21. |
Bunting, K. D., Galipeau, J., Topham, D., Benaim, E., and Sorrentino, B. P. (1998) Transduction of murine bone marrow cells
with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in
transplanted mice. Blood
92, 2269–2279.
|
| |
| 22. |
Sorrentino, B. P., McDonagh, K. T., Woods, D., and Orlic, D. (1995) Expression of retroviral vectors containing the human
multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood
86, 491–501.
|
| |
| 23. |
Allay, J. A., Dumenco, L. L., Koc, O. N., Liu, L., and Gerson, S. L. (1995) Retroviral transduction and expression of the
human alkyltransferase cDNA provides nitrosource resistance to hematopoietic cells. Blood
85, 3342–3351.
|
| |
| 24. |
Allay, J. A., Davis, B. M., and Gerson, S. L. (1997) Human alkyltransferase-transduced murine myeloid progenitors are enriched
in vivo by BCNU treatment of transplanted mice. Exp. Hematol. 25, 1069–1076.
|
| |
| 25. |
Corey, C. A., DeSilva, A. D., Holland, C. A., and Williams, D. A. (1990) Serial transplantation of methotrexate-resistant
bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood
75, 337–343.
|
| |
| 26. |
Zhao, S. C., Li, M. X., Banerjee, D., Schweitzer, B. I., Mineishi, S., Gilboa, E., and Bertino, J. R. (1994) Long-term protection
of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant
dihydrofolate reductase. Cancer Gene Ther. 1, 27–33.
|
| |
| 27. |
Allay, J. A., Galipeau, J., Blakley, R. L., and Sorrentino, B. P. (1998) Retroviral vectors containing a variant dihydrofolate
reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells
16 Suppl 1, 223–233.
|
| |
| 28. |
Matsunaga, T., Sakamaki, S., Kuga, T., Kuroda, H., Kusakabe, T., Akiyama, T., Konuma, Y., Hirayama, Y., Kobune, M., Kato,
J., Sasaki, K., Kogawa, K., Koyama, R., and Niitsu, Y. (2000) GST-pi gene-transduced hematopoietic progenitor cell transplantation
overcomes the bone marrow toxicity of cyclophosphamide in mice. Hum. Gene Ther. 11, 1671–1681.
|
| |
| 29. |
Momparler, R. L., Eliopoulos, N., Bovenzi, V., Letourneau, S., Greenbaum, M., and Cournoyer, D. (1996) Resistance to cytosine
arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
Cancer Gene Ther. 3, 331–338.
|
| |
| 30. |
Rattmann, I., Kleff, V., Sorg, U. R., Bardenheuer, W., Brueckner, A., Hilger, R. A., Opalka, B., Seeber, S., Flasshove, M.,
and Moritz, T. (2006) Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine
transplant model. Blood
108, 2965–2971.
|
| |
| 31. |
Flasshove, M., Frings, W., Schroder, J. K., Moritz, T., Schutte, J., and Seeber, S. (1999) Transfer of the cytidine deaminase
cDNA into hematopoietic cells. Leuk. Res. 23, 1047–1053.
|
| |
| 32. |
Magni, M., Shammah, S., Schiro, R., Mellado, W., la-Favera, R., and Gianni, A. M. (1996) Induction of cyclophosphamide-resistance
by aldehyde-dehydrogenase gene transfer. Blood
87, 1097–1103.
|
| |
| 33. |
Bunting, K. D., Townsend, A. J. (1996) Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic
effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the
human cytosolic class 3 isozyme. J. Biol. Chem. 271, 11891–11896.
|
| |